Taho Pharmaceuticals Ltd. (TPEX:6467)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
196.00
+2.00 (1.03%)
At close: Sep 19, 2025
1.03%
Market Cap10.10B
Revenue (ttm)7.78M
Net Income (ttm)-165.97M
Shares Out51.39M
EPS (ttm)-3.37
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume601,316
Average Volume965,854
Open195.00
Previous Close194.00
Day's Range192.00 - 196.50
52-Week Range32.25 - 208.50
Beta-59.71
RSI65.74
Earnings DateNov 13, 2025

About Taho Pharmaceuticals

Taho Pharmaceuticals Ltd., a pharmaceutical company, develops products using transdermal and transmucosal systems in Taiwan. The company’s portfolio includes TAH4411 Ondansetron ODF for the treatment of chemotherapy-induced nausea and vomiting; TAH3311 apixaban oral film, which is in phase 3 clinical trial for patients with Dysphagia; TAH3341 apixaban oral extend release film for patients with Dysphagia; TAH2211 Buprenorphine/Naloxone sublingual film, which is in phase 1 clinical trial for opioid addiction; TAH2231 Naloxone Buccal film , which ... [Read more]

Industry Pharmaceutical Preparations
Founded 2010
Employees 27
Stock Exchange Taipei Exchange
Ticker Symbol 6467
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.